Exploring the Therapeutic Potential of Psychedelics in Chronic Pain Management: A New Frontier in Medicine

Chronic pain, characterized by pain lasting for more than three months, is a debilitating condition frequently caused by conditions such as fibromyalgia, arthritis, neuropathy, and migraine [1–3]. Beyond its physical implications, chronic pain significantly impacts mental health, frequently leading to conditions like depression and anxiety [4]. Traditional treatments, including opioids and nonsteroidal anti-inflammatory drugs, often prove inadequate, leaving many sufferers in a state of persistent discomfort and diminished quality of life [5]. These conventional therapies are further complicated by adverse side-effects, the potential for addiction, and often insufficient analgesic efficacy, highlighting a critical need for novel therapeutic strategies.

The search for new pain management solutions has brought attention to the therapeutic potential of psychedelics such as psilocybin (the active compound in psychedelic mushrooms), and lysergic acid diethylamide (LSD) [6]. While the majority of current research and development activity is focused on treating depression and substance use disorders, numerous reports suggest that psychedelics might also offer therapeutic benefits for other medical conditions, including headache disorders and chronic pain. This perspective examines various factors related to using psychedelics in chronic pain disorders and explores key findings, potential mechanisms, and future directions for treating chronic pain.

The therapeutic potential of psychedelics in managing various types of chronic pain is an emerging area of interest within the medical community (Table 1). Psilocybin has shown promise in treating chronic pain conditions such as migraines and cluster headaches. Studies have shown that psilocybin can significantly reduce the frequency and severity of cluster headache attacks and has enduring therapeutic effects for migraine headaches after a single administration. Moreover, psilocybin has been well-tolerated in clinical settings, with no unexpected or serious adverse events or withdrawals due to adverse events. Similarly, psilocybin may also alleviate the symptoms of fibromyalgia, a condition characterized by widespread pain and fatigue. Psychotherapy is undergoing a Phase 2a clinical trial (NCT05128162) to evaluate the efficacy of psilocybin on pain perception and quality of life in fibromyalgia patients. These studies highlight the potential of psilocybin as a viable and safe treatment option for chronic pain management.

Table 1.

Clinical trials related to the use of psychedelics in pain management

Psychedelic	Pain condition	Clinical trial number	Study phase
Psilocybin	Migraine and cluster headaches	NCT02981173	Phase 1
Psilocybin	Neuropathic pain	NCT06518720	Phase 2
Psilocybin	Headache disorders	NCT06464367	Early phase 1
Psilocybin	Fibromyalgia	NCT06368492	Not applicable
Psilocybin	Low back pain	NCT06355414	Phase 1
Psilocybin	Cancer pain	NCT06001749	Phase 2
Psilocybin	Chronic pain	NCT05506982	Phase 1
Psilocybin	Low back pain	NCT05351541	Phase 1, Phase 2
Psilocybin	Phantom limb pain	NCT05224336	Phase 1
Psilocybin	Fibromyalgia	NCT05128162	Phase 2
Psilocybin	Chronic pain	NCT05068791	Early Phase 1
Psilocybin	Migraine headache	NCT04218539	Phase 1
Psilocybin	Fibromyalgia	NCT05548075	Phase 1
Psilocybin	Migraine headache	NCT03341689	Phase 2
Psilocybin	Cancer pain	NCT04593563	Phase 2
LSD	Cluster headache	NCT03781128	Phase 2
LSD	Cluster headache	NCT05477459	Phase 2

Several studies and clinical trials have highlighted LSD’s potential benefits in managing chronic pain. A seminal study by Kast in 1964 showed substantial pain relief in terminal cancer patients administered LSD, underscoring its potential in severe pain scenarios. Recent studies have renewed interest in the analgesic properties of LSD, demonstrating that a non-hallucinogenic dose can significantly lower pain perception and enhance emotional well-being in healthy volunteers. This suggests that LSD could be a viable alternative to traditional opioid painkillers, providing similar effects on pain tolerance and perception while causing fewer severe side-effects. These findings underscore the need for further research into LSD’s long-term efficacy and safety in pain management, particularly for conditions such as fibromyalgia and end-of-life pain.

The therapeutic potential of psychedelics in treating chronic pain involves several unique mechanisms of action. Firstly, psychedelics enhance neuroplasticity, enabling the brain to reorganize by forming new neural connections [7]. This increased plasticity can help “reset” the neural pathways associated with chronic pain, thereby disrupting the cycle of pain and negative emotional responses. Enhanced connectivity between different brain regions can promote the development of new coping mechanisms for pain management, with effects that last long after the drug’s half-life has expired. Secondly, psychedelics primarily act on the brain’s serotonin receptors, particularly the 5-HT2A receptor, which can alter pain perception and reduce the emotional distress associated with chronic pain [8]. Thirdly, some psychedelics possess anti-inflammatory properties, which can alleviate pain symptoms by decreasing pro-inflammatory cytokines [9]. Lastly, chronic pain is often closely linked with emotional and cognitive processes. Psychedelic experiences can facilitate deep emotional processing, allowing individuals to address underlying trauma or emotional pain that may exacerbate their physical symptoms [10]. These combined mechanisms underscore the potential of psychedelics as a novel and multifaceted approach to pain management.

The therapeutic use of psychedelics for pain management can be categorized into full-dose and microdosing regimens, each with distinct implications for efficacy and subjective experience [11]. Full doses, which are large enough to generate significant alterations in consciousness, are often perceived to provide more effective pain relief than microdosing. Microdosing, involving smaller doses taken repeatedly over time, has shown efficacy comparable to conventional treatments, particularly for headache disorders, without producing perceivable alterations in consciousness. Notably, studies indicate that the analgesic effects of psychedelics can occur independently of their acute psychotropic effects, suggesting that effective pain relief does not necessarily require the profound subjective experiences associated with higher doses. This separation of psychological and therapeutic outcomes highlights the need for further research to understand the underlying mechanisms, optimize dosing protocols, and evaluate the role of both pharmacologic and extra-pharmacologic factors. By allowing flexibility and adaptation in treatment protocols, future studies can better assess the potential of psychedelics in managing chronic pain.

While psychedelics are generally considered to be relatively safe from a physiological standpoint, they can lead to a range of side-effects, including mental health concerns, physical symptoms, tolerance, and potential lethality [12]. Short-term psychological effects may include anxiety, paranoia, hallucinations, derealization, and depersonalization. Long-term psychological risks involve hallucinogen-persisting perception disorder, mood disorders, and the possibility of psychological dependence. Physical symptoms can range from nausea, vomiting, and increased heart rate or blood pressure to dizziness, muscle weakness, seizures, hyperthermia, and serotonin syndrome. Tolerance develops rapidly but is reversible, with some risk of psychological dependence. Lethality risks include overdose potential, indirect harm, and risky behaviors. To reduce these risks, the principles of “set and setting” play a crucial role in harm reduction. “Set” refers to an individual’s mindset, encompassing their expectations, mood, and psychological state, while “setting” involves the environmental factors, including the physical surroundings and social context during the psychedelic experience. By properly managing these elements, the risk of adverse reactions can be substantially minimized. Ensuring a supportive and controlled environment, along with psychological preparation and integrative support, can enhance the safety and therapeutic outcomes of psychedelic treatments for chronic pain. This comprehensive approach not only maximizes benefits but also minimizes potential risks, making the therapeutic use of psychedelics a more viable option for pain management.

Despite the promising potential of psychedelics in treating chronic pain, several challenges and considerations need to be addressed to fully realize their therapeutic benefits. One of the main hurdles is the legal and regulatory status of psychedelics, which are classified as Schedule I substances in many countries, indicating a high potential for abuse and no accepted medical use. This classification poses significant barriers to research and clinical application. Safety is another critical concern; although psychedelics are generally regarded as safe when administered in controlled settings, they can trigger psychological distress, particularly in individuals with a history of mental health conditions. Therefore, careful screening and monitoring are essential to ensure patient safety. Moreover, the profound and sometimes challenging nature of psychedelic experiences necessitates ongoing psychological support and integration therapy to maximize benefits and ensure long-term improvements in pain management. Individual variability in responses to psychedelics, influenced by factors such as genetics, personality, and prior experiences, further complicates treatment protocols, necessitating personalized approaches tailored to each patient’s specific needs. In addition, the stigma associated with psychedelic use due to its recreational drug history presents a significant obstacle, requiring comprehensive public and professional education to foster acceptance and integration into mainstream medicine. Lastly, although the head twitch response is a valuable and widely accepted model in psychedelic research that aids in understanding their hallucinogenic potential during preclinical studies, it does not encompass the full complexity of human psychedelic experiences, particularly regarding cognitive, emotional, and long-term therapeutic effects. A comprehensive evaluation of these effects requires a multifaceted approach that incorporates subjective self-reporting, standardized psychometric tools, biological measurements, and behavioral observations. Together, these methods enable researchers and clinicians to gain insights into both the immediate and lasting impacts of psychedelic substances on perception, cognition, emotion, and physical well-being. Addressing these challenges through rigorous research, careful clinical application, and public education is crucial for harnessing the full potential of psychedelics in chronic pain management.

The future of psychedelics in chronic pain management holds considerable promise, with several key areas for further exploration and development. First, larger and more randomized controlled clinical trials are necessary to confirm the efficacy and safety of psychedelic treatments for various pain conditions across diverse populations. Research should also focus on developing new psychedelic compounds with optimized therapeutic profiles and minimized side-effects. Integrating psychedelics into existing pain management protocols could offer a holistic approach, combining pharmacological, psychological, and cognitive-behavioral therapy and physical rehabilitation. In addition, training healthcare providers on the potential benefits and risks of psychedelic therapy is crucial for its safe and effective implementation, necessitating comprehensive education programs covering screening, administration, and integration support. Addressing these directions will help to realize the full potential of psychedelics in chronic pain management, providing innovative solutions for patients in need.

In conclusion, psychedelics represent a promising new frontier in chronic pain management, offering benefits that extend beyond symptom relief to profound psychological and emotional healing. Evidence suggests that psychedelics can enhance neuroplasticity, modulate serotonin receptors, reduce inflammation, and facilitate deep emotional processing. Despite these promising findings, further research is necessary to fully understand their therapeutic potential and safety. Controlled clinical trials are essential to confirm their efficacy and explore long-term effects on various chronic pain conditions. As research continues to evolve, integrating psychedelics into holistic pain management strategies could provide much-needed relief for millions suffering from chronic pain. Ongoing research, education, and advocacy are crucial to ensure these therapies are safe, effective, and accessible to all who need them. While psychedelics show potential for pain reduction, additional studies are needed to assess their long-term effectiveness.

Conflict of interests

The authors declare no competing interests.